Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Exclusion Criteria

• •Patients with active disease or active double cancers other than target lesions.
• •Patients with imaging findings that affect imaging evaluation of the tumor, such as ground-glass opacities
• •Patients who received radiation therapy exceeding 65 Gy as a prior treatment for the target lesion.
• •Any serious concomitant disease that precludes completion of the study treatment.
• •Patients with remaining complications of Grade 3 or higher related to prior radiation therapy in the irradiation field.